NEW YORK (GenomeWeb) – Fluidigm continues to profit from sales of its C1 Single-Cell Auto Prep System. The company this week reported organic revenue growth of 58 percent, driven largely by sales of the C1 as well as the BioMark HD Systems bundled together with it.
Correction: The story has been updated to include the correct net proceed amount from the sale. NEW YORK (GenomeWeb News) – Fluidigm said after the close of the market on Tuesday it has closed on the sale of about $201.3 million of senior convertible notes.
NanoString Technologies last week reported a 39 percent increase in third quarter revenues while company executives offered an overview of the Seattle-based company's opportunities in the molecular diagnostics and life science research markets.